SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic program, underscoring continued pharmaceutical interest in genetic medicines ...

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and implications for molecular biology research.

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

The therapy is designed to silence both PCSK9 and APOC3 genes simultaneously.

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...